Caribou Biosciences to Present at Upcoming Investor Conferences
November 17 2021 - 4:05PM
Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, announced today
that Rachel Haurwitz, Ph.D., Caribou’s president and chief
executive officer, will participate in the following upcoming
investor conferences.
- Piper Sandler 33rd
Annual Virtual Healthcare ConferenceNovember 30 –
December 2, with a fireside chat webcast available beginning
Wednesday, November 24
- Evercore ISI 4th
Annual HealthCONx ConferenceNovember 30 – December
2, with a fireside chat at 4:20 – 4:40 PM ET on Thursday, December
2
Webcasts of the discussions will be accessible via Caribou’s
website on the Events page. Archived copies of the webcasts will be
available on the Caribou website for 30 days after the events.
About Caribou’s Novel Next-Generation CRISPR
PlatformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Type II CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems
occasionally edit unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
chRDNAs (pronounced “chardonnays”), RNA-DNA hybrid guides that
direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of the chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.Caribou is a
clinical-stage CRISPR genome-editing biopharmaceutical company
dedicated to transforming the lives of patients with devastating
diseases by applying the company’s proprietary chRDNA technology
toward the development of next-generation, genome-edited cell
therapies. The company is developing a pipeline of genome-edited,
off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of
both hematologic malignancies and solid tumors against cell surface
targets for which autologous CAR-T cell therapeutics have
previously demonstrated clinical proof of concept, as well as
additional emerging targets.
For more information about Caribou, visit www.cariboubio.com and
follow the company @CaribouBio.
“Caribou Biosciences” and the Caribou logo are registered
trademarks of Caribou Biosciences, Inc.
Caribou Biosciences, Inc.
Contact:Amy Figueroa, CFAInvestor Relations and
Corporate Communicationsafigueroa@cariboubio.com
Investors:Elizabeth Wolffe, Ph.D., and Sylvia
WheelerWheelhouse
LSAlwolffe@wheelhouselsa.comswheeler@wheelhouselsa.com
Media: Greg
KelleyOgilvygregory.kelley@ogilvy.com 617-461-4023
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024